- 全部删除
您的购物车当前为空
PNU 74654是一种Wnt/β-catenin 通路抑制剂,在NCI-H295 细胞中的IC50值为129.8 μM。


为众多的药物研发团队赋能,
让新药发现更简单!
PNU 74654是一种Wnt/β-catenin 通路抑制剂,在NCI-H295 细胞中的IC50值为129.8 μM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 172 | In stock | |
| 5 mg | ¥ 438 | In stock | |
| 10 mg | ¥ 638 | In stock | |
| 25 mg | ¥ 1,390 | In stock | |
| 50 mg | ¥ 2,490 | In stock | |
| 100 mg | ¥ 3,770 | In stock | |
| 200 mg | ¥ 5,390 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 483 | In stock |
PNU-74654 相关产品
| 产品描述 | PNU 74654 binds to β-catenin (Kd = 450 nM), inhibiting its interaction with the transcription factor T cell factor 4 (Tcf4) resulting in disruption of the Wnt signaling pathway. |
| 靶点活性 | Wnt/β-catenin (NCI-H295 cells):129.8 μM |
| 体外活性 | 在NCI-H295细胞中,PNU 74654在治疗后96小时显著降低了细胞增殖,增加了早期和晚期凋亡,降低了核内beta-catenin积累,损害了CTNNB1/beta-catenin表达,并在治疗后48小时提高了beta-catenin目标基因的表达。HeLa细胞未观察到效应。在NCI-H295细胞中,PNU 74654在治疗后24小时和48小时降低了cortisol、testosterone和androstenedione的分泌。此外,在NCI-H295细胞中,PNU 74654在治疗后48小时降低了SF1和CYP21A2 mRNA的表达,以及STAR和aldosterone synthase的蛋白水平。在Y1细胞中,PNU 74654在治疗后24小时损害了corticosterone分泌,但未减少细胞活力[1]。 |
| 细胞实验 | Adrenal (NCI-H295 and Y1) and non-adrenal (HeLa) cell lines were treated with PNU 74654 (5-200 μM) for 24-96 h to assess cell viability (MTS-based assay), apoptosis (Annexin V), expression/localization of beta-catenin (qPCR, immunofluorescence, immunocytochemistry and western blot), expression of beta-catenin target genes (qPCR and western blot), and adrenal steroidogenesis (radioimmunoassay, qPCR and western blot)[1]. |
| 分子量 | 320.34 |
| 分子式 | C19H16N2O3 |
| CAS No. | 113906-27-7 |
| Smiles | Cc1ccc(\C=N\NC(=O)c2ccccc2Oc2ccccc2)o1 |
| 密度 | 1.17 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 30 mg/mL (93.65 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.24 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容